Geode Capital Management
ACTU

Geode Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Geode Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$626K Buy
228,331
+20,587
+10% +$85.3K ﹤0.01% 3510
2025
Q4 		$1.27M Buy
207,744
+62,332
+43% +$428K ﹤0.01% 3308
2025
Q3 		$973K Buy
145,412
+27,362
+23% +$198K ﹤0.01% 3386
2025
Q2 		$721K Buy
118,050
+84,561
+253% +$739K ﹤0.01% 3434
2025
Q1 		$227K Buy
33,489
+5,596
+20% +$44.9K ﹤0.01% 3801
2024
Q4 		$222K Hold
27,893
– – ﹤0.01% 3870
2024
Q3 		$208K Buy
+27,893
New +$221K ﹤0.01% 3891

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Geode Capital Management's ACTU Position: Q1 2026 in Review

Geode Capital Management increased its Actuate Therapeutics (ACTU) stake by 9.9% in Q1 2026, buying an estimated $85.3K and bringing the position to 228,331 shares worth $626K. The position accounts for ﹤0.01% of the portfolio, ranked #3510.

Geode Capital Management first reported a position in ACTU in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.27M in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Geode Capital Management held 228,331 shares of Actuate Therapeutics worth $626K as of Q1 2026.
  • Geode Capital Management bought 20,587 Actuate Therapeutics shares in Q1 2026, an estimated $85.3K.
  • Actuate Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3510 holding.
  • Geode Capital Management first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Geode Capital Management's Actuate Therapeutics position peaked at $1.27M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.